Go Pro
→ They didn't warn anyone in 1971. This time someone is warning you. (From Reagan Gold Group) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Athersys, Inc. stock logo
ATHX
Athersys
$0.00
$0.01
▼
$1.99
$833K-0.91.77 million shsN/A
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
$0.01
+4.0%		$0.01
$0.01
▼
$5.72
$745K0.19675,496 shs401,180 shs
PainReform Ltd. stock logo
PRFX
PainReform
$0.86
-7.3%		$1.09
$0.85
▼
$7.95
$810K1.05106,769 shs88,064 shs
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
$0.00
$0.00
▼
$0.05
$221K0.11261,475 shs73,281 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Athersys, Inc. stock logo
ATHX
Athersys
0.00%0.00%0.00%0.00%0.00%
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
-9.09%-16.67%-6.54%-9.09%-99.80%
PainReform Ltd. stock logo
PRFX
PainReform
-2.40%-5.28%-15.68%-31.80%-86.36%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
-20.00%-33.33%0.00%-55.56%-80.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Athersys, Inc. stock logo
ATHX
Athersys
$0.00
$0.01
▼
$1.99
$833K-0.91.77 million shsN/A
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
$0.01
+4.0%		$0.01
$0.01
▼
$5.72
$745K0.19675,496 shs401,180 shs
PainReform Ltd. stock logo
PRFX
PainReform
$0.86
-7.3%		$1.09
$0.85
▼
$7.95
$810K1.05106,769 shs88,064 shs
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
$0.00
$0.00
▼
$0.05
$221K0.11261,475 shs73,281 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Athersys, Inc. stock logo
ATHX
Athersys
0.00%0.00%0.00%0.00%0.00%
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
-9.09%-16.67%-6.54%-9.09%-99.80%
PainReform Ltd. stock logo
PRFX
PainReform
-2.40%-5.28%-15.68%-31.80%-86.36%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
-20.00%-33.33%0.00%-55.56%-80.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Athersys, Inc. stock logo
ATHX
Athersys
0.00
N/AN/AN/A
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
1.67
Reduce$30.00288,361.54% Upside
PainReform Ltd. stock logo
PRFX
PainReform
1.00
SellN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SRNE, PRFX, ATHX, and CERO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
PainReform Ltd. stock logo
PRFX
PainReform
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Athersys, Inc. stock logo
ATHX
Athersys
$146K0.00N/AN/A($1.33) per share0.00
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
N/AN/AN/AN/A($41.98) per shareN/A
PainReform Ltd. stock logo
PRFX
PainReform
$20K37.41N/AN/A$23.07 per share0.04
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$60.32M0.00N/AN/AN/A∞
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Athersys, Inc. stock logo
ATHX
Athersys
-$72.53M-$2.03N/AN/AN/AN/AN/A-223.03%N/A
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
-$8.30M-$9.84N/AN/AN/AN/AN/A-209.40%N/A
PainReform Ltd. stock logo
PRFX
PainReform
-$5.02M-$736.66N/AN/AN/AN/AN/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
-$572.84M-$0.17N/AN/AN/AN/AN/AN/A11/6/2026 (Estimated)

Latest SRNE, PRFX, ATHX, and CERO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/3/2026Q2 2026
PainReform Ltd. stock logo
PRFX
PainReform
N/A-$1.13N/A-$1.1250N/A$0.01 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Athersys, Inc. stock logo
ATHX
Athersys
N/AN/AN/AN/AN/A
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
N/AN/AN/AN/AN/A
PainReform Ltd. stock logo
PRFX
PainReform
N/AN/AN/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Athersys, Inc. stock logo
ATHX
Athersys
N/A
0.06
0.06
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
N/A
0.56
0.56
PainReform Ltd. stock logo
PRFX
PainReform
N/A
5.07
1.78
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Athersys, Inc. stock logo
ATHX
Athersys
19.35%
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
29.64%
PainReform Ltd. stock logo
PRFX
PainReform
37.28%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.02%

Insider Ownership

CompanyInsider Ownership
Athersys, Inc. stock logo
ATHX
Athersys
0.03%
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
0.36%
PainReform Ltd. stock logo
PRFX
PainReform
34.40%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
2.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Athersys, Inc. stock logo
ATHX
Athersys
2461.72 million61.70 millionNo Data
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
871.63 million1.05 millionN/A
PainReform Ltd. stock logo
PRFX
PainReform
4870,000570,000Not Optionable
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
800551.28 million536.95 millionNo Data

Recent News About These Companies

Sorrento Voyage Announces Expanded Luxury Boat Tours and Proposal Experiences Along the Amalfi Coast
January 5, 2026  |  newsfilecorp.comN
Sorrento Therapeutics Inc (SRNE) - Investing.com
July 3, 2025  |  investing.comhttps://www.investing.com/equities/sorrento-therape-opinion
SRNE Sorrento Therapeutics, Inc. - Seeking Alpha
June 29, 2025  |  seekingalpha.comhttps://seekingalpha.com/symbol/SRNE
Sorrento Therapeutics Stock Price, Quotes and Forecasts | OTC:SRNE | Benzinga
April 19, 2025  |  benzinga.comhttps://www.benzinga.com/quote/SRNE
Sorrento Shareholders Lose Discovery Bid Over Judge Relationship
March 28, 2025  |  news.bloomberglaw.comN
Scilex says bankruptcy court extends lockup period on shares of Scilex dividend
January 31, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/scilex-says-bankruptcy-court-extends-lockup-period-on-shares-of-scilex-dividend-1034296170
DSI Introduces Westbury Sorrento Aluminum Railing with Bold Distinctive Mesh Stainless Steel Infills
October 24, 2024  |  newsfilecorp.comN
Sorrento enrols 60 of 80-patient Phase II target for abivertinib in Covid-19; futility analysis potentially in a month, CEO says
August 20, 2024  |  msn.comhttps://www.msn.com/en-us/health/medical/sorrento-enrols-60-of-80-patient-phase-ii-target-for-abivertinib-in-covid-19-futility-analysis-potentially-in-a-month-ceo-says/ar-AA1p7arP
Sorrento Resources to Sell Three Newfoundland Properties to Gold Hunter
May 29, 2024  |  newsfilecorp.comN
Sorrento Therapeutics Inc (SRNE)
May 25, 2024  |  investing.comhttps://www.investing.com/equities/sorrento-therape-opinion/3
Sorrento Resources Announces Appointment of Alex Bugden as a Director and Qualified Person
May 8, 2024  |  newsfilecorp.comN
DSI Introduces Westbury(R) Sorrento Aluminum and Stainless Steel Mesh Railing
May 1, 2024  |  newsfilecorp.comN
Sorrento Therapeutics Inc SRNE
April 26, 2024  |  morningstar.comM
Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks
March 27, 2024  |  news.bloomberglaw.comN
Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks
March 27, 2024  |  news.bloomberglaw.comN
Sorrento Defeats DOJ Effort to Move Bankruptcy Out of Texas (1)
March 12, 2024  |  news.bloomberglaw.comN
Judge Declines to Dismiss Sorrento Therapeutics Bankruptcy Case
March 12, 2024  |  wsj.comhttps://www.wsj.com/articles/judge-declines-to-dismiss-sorrento-therapeutics-bankruptcy-case-8321bd69
Sorrento Therapeutics
February 7, 2024  |  pharmaphorum.comP
5 Sanders Cove, Sorrento WA 6020
January 18, 2024  |  domain.com.auD
Sorrento Therapeutics, Inc. (0L85.L)
January 9, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/quote/0L85.L/history/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Athersys stock logo

Athersys NASDAQ:ATHX

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.

CERo Therapeutics stock logo

CERo Therapeutics NASDAQ:CERO

$0.01 +0.00 (+4.00%)
As of 02:49 PM Eastern

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

PainReform stock logo

PainReform NASDAQ:PRFX

$0.86 -0.07 (-7.27%)
Closing price 04:00 PM Eastern
Extended Trading
$0.90 +0.04 (+5.22%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

Sorrento Therapeutics stock logo

Sorrento Therapeutics NASDAQ:SRNE

$0.0004 0.00 (0.00%)
As of 03:31 PM Eastern

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas